Devices and methods for non-invasive multi-wavelength photobiomodulation for ocular treatments

Abstract

An ophthalmic phototherapy device and associated treatment methods to expose an eye to selected multi-wavelengths of light to promote the healing of damaged or diseased eye tissue. The device includes a housing having an interior; an eyepiece disposed on the housing and configured and arranged for placement of an eye of the patient adjacent the eyepiece; a first light source producing a first light beam having a first therapeutic wavelength and disposed within the housing; a second light source producing a second light beam having a second therapeutic wavelength and disposed within the housing, where the second therapeutic wavelength differs from the first therapeutic wavelength by at least 25 nm.

1 .- 23 . (canceled) 
     
     
         24 . A device for delivery of photobiomodulation (PBM) to a target cell or tissue of at least one eye of a patient, the device comprising:
 an eyepiece or eyebox through which PBM light from the device is delivered to the at least one eye of the patient;   at least one light source, wherein the at least one light source is configured to produce a first light beam having a first therapeutic wavelength and a second light beam having a second therapeutic wavelength, wherein the second therapeutic wavelength differs from the first therapeutic wavelength by at least 25 nm;   a relay structure that, in operation, directs the first light beam and the second light beam to the eyepiece or eyebox to provide PBM to the target cell or tissue of the at least one eye of the patient; and   an actuator configured to move at least a portion of the relay structure to change a direction of at least one of the first light beam or the second light beam relative to the at least one eye of the patient.   
     
     
         25 . The device of  claim 24 , further comprising a programmable controller operatively coupled to the at least one light source, wherein the programmable controller is configured to control, for at least one of the first light beam and the second light beam: a light energy emission; a light energy density; a light energy duration; a light energy frequency; a light energy area; a light energy sequence; or any combination thereof. 
     
     
         26 . The device of  claim 24 , further comprising an aperture, wherein the device is configured to direct the first light beam and the second light beam through the aperture and through the eyepiece or eyebox to provide PBM to the target cell or tissue of the at least one eye of the patient. 
     
     
         27 . The device of  claim 24 , further comprising a reflective filter configured to substantially pass light having the first therapeutic wavelength and substantially reflect light having the second therapeutic wavelength, wherein the device is configured to direct the first light beam and the second light beam to the reflective filter and to direct the light having the first therapeutic wavelength and the light having the second therapeutic wavelength through the eyepiece or eyebox to provide PBM to the target cell or tissue of said at least one eye. 
     
     
         28 . The device of  claim 24 , wherein the at least one light source comprises an LED, a lamp, a laser, or any combination thereof. 
     
     
         29 . The device of  claim 24 , wherein the at least one light source is configured to emit a pulsed light beam comprising a plurality of pulses having a temporal pulse width, wherein the temporal pulse width is in a range from 0.1 milliseconds to 150 seconds. 
     
     
         30 . The device of  claim 24 , wherein the first therapeutic wavelength is in a range from 800 to 900 nm and the second therapeutic wavelength is in a range from 600 to 700 nm. 
     
     
         31 . The device of  claim 24 , wherein the first therapeutic wavelength is in a range from 800 to 900 nm and the second therapeutic wavelength is in a range from 550 to 650 nm. 
     
     
         32 . The device of  claim 24 , wherein one or both of the first therapeutic wavelength and the second therapeutic wavelength are in a range of 590 nm±10%, 670 nm±10%, 810 nm±10%, or 1064 nm±10%. 
     
     
         33 . The device of  claim 24 , wherein the first therapeutic wavelength or the second therapeutic wavelength is in a range of:
 (i) 850±30 nm;   (ii) 660±30 nm; or   (iii) 590±30 nm.   
     
     
         34 . The device of  claim 24 , wherein the first therapeutic wavelength and the second therapeutic wavelength are:
 (i) 590 nm±10% and 670 nm±10%, respectively;   (ii) 670 nm±10% and 590 nm±10%, respectively;   (iii) 590 nm±10% and 810 nm±10%, respectively;   (iv) 810 nm±10% and 590 nm±10%, respectively;   (v) 590 nm±10% and 1064 nm±10%, respectively;   (vi) 1064 nm±10% and 590 nm±10%, respectively;   (vii) 670 nm±10% and 810 nm±10%, respectively;   (viii) 810 nm±10% and 670 nm±10%, respectively;   (ix) 670 nm±10% and 1064 nm±10%, respectively;   (x) 1064 nm±10% and 670 nm±10%, respectively;   (xi) 810 nm±10% and 1064 nm±10%, respectively; or   (xii) 1064 nm±10% and 810 nm±10%, respectively.   
     
     
         35 . The device of  claim 24 , wherein the at least one light source is configured to produce a third light beam having a third therapeutic wavelength, wherein the third therapeutic wavelength differs from the first therapeutic wavelength and the second therapeutic wavelength by at least 25 nm. 
     
     
         36 . The device of  claim 35 , wherein the first therapeutic wavelength, the second therapeutic wavelength, and the third therapeutic wavelength are each selected from a yellow wavelength, a red wavelength, or a near-infrared wavelength. 
     
     
         37 . The device of  claim 35 , wherein the first therapeutic wavelength is in a range from 800 nm to 900 nm, the second therapeutic wavelength is in a range from 600 to 700 nm, and the third wavelength is in a range from 550 to 650 nm. 
     
     
         38 . The device of  claim 37 , wherein the first therapeutic wavelength is in a range of 850 nm±30 nm, the second therapeutic wavelength is in a range of 660±30 nm, and the third wavelength is in a range of 590±30 nm. 
     
     
         39 . The device of  claim 24 , further comprising a beam positioning mechanism operably coupled to the actuator to move at least a portion of the relay structure. 
     
     
         40 . The device of  claim 25 , further comprising a biomedical sensor operatively coupled to the programmable controller and configured to provide real-time feedback information regarding the at least one eye of the patient. 
     
     
         41 . The device of  claim 40 , wherein the programmable controller is configured to regulate emission of light from the at least one light source in accordance with the feedback information. 
     
     
         42 . The device of  claim 24 , further comprising:
 (i) a patient interface that includes a forehead rest, a chin rest, or both a forehead rest and a chin rest;   (ii) a user interface; or   (iii) both of (i) and (ii).   
     
     
         43 . A method of delivering PBM to a target cell or tissue of at least one eye of a patient using the device of  claim 24 , the method comprising:
 (i) placing the at least one eye of the patient at the eyepiece or eyebox of the device; and   (ii) directing light of at least one of the first therapeutic wavelength or the second therapeutic wavelength from the device to the at least one eye of the patient.